Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.
Granite Bio has raised $70.0M in total funding. The most recent round was Series B. The last funding was announced in April 2025.
Granite Bio's investors include Versant Ventures, Forbion Capital Partners, Novartis Venture Fund, Sanofi Ventures.
Granite Bio is headquartered in Basel, Switzerland.
Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.
Granite Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Granite Bio — Funding & Investors." VCBacked, April 24, 2025, https://www.vcbacked.co/company/granite-bio. Accessed September 15, 2026.
VCBacked. (2025). Granite Bio — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/granite-bio
{{cite web |title=Granite Bio — Funding & Investors |url=https://www.vcbacked.co/company/granite-bio |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated